CTLA4 and melanoma: These findings confirm the presence of an “obesity paradox” recently reported in advanced melanoma patients treated with immune checkpoint inhibition (anti-PD-1/anti-CTLA-4 monotherapy) or targeted therapy in a pooled meta-analysis [19], albeit for overweight/Class I obesity in this study.